How Much Longer Will We Put Up With 100,000 Cancer Drugs?

Paul Workman; Giulio F. Draetta; Jan H.M. Schellens; René Bernards

doi:10.1016/j.cell.2017.01.034

How Much Longer Will We Put Up With 100,000 Cancer Drugs?

Paul Workman, Giulio F. Draetta, Jan H.M. Schellens, René Bernards

Genomic Medicine

Research output: Contribution to journal › Comment/debate › peer-review

62 Scopus citations

Abstract

The spiraling cost of new drugs mandates a fundamentally different approach to keep lifesaving therapies affordable for cancer patients. We call here for the formation of new relationships between academic drug discovery centers and commercial partners, which can accelerate the development of truly transformative drugs at sustainable prices.

Original language	English (US)
Pages (from-to)	579-583
Number of pages	5
Journal	Cell
Volume	168
Issue number	4
DOIs	https://doi.org/10.1016/j.cell.2017.01.034
State	Published - Feb 9 2017

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.cell.2017.01.034

Cite this

@article{e2e2da7229814128b39244fa41d957a6,

title = "How Much Longer Will We Put Up With 100,000 Cancer Drugs?",

abstract = "The spiraling cost of new drugs mandates a fundamentally different approach to keep lifesaving therapies affordable for cancer patients. We call here for the formation of new relationships between academic drug discovery centers and commercial partners, which can accelerate the development of truly transformative drugs at sustainable prices.",

author = "Paul Workman and Draetta, {Giulio F.} and Schellens, {Jan H.M.} and Ren{\'e} Bernards",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = feb,

day = "9",

doi = "10.1016/j.cell.2017.01.034",

language = "English (US)",

volume = "168",

pages = "579--583",

journal = "Cell",

issn = "0092-8674",